About Dr. Vincent (Wentao) Fang
Wentao Fang, MD, Professor Current position: Deputy Chief, Department of Thoracic Surgery, Shanghai Chest Hospital Chief, Division of Mediastinal Surgery, Shanghai Chest Hospital Chief Director, Clinical Center for Esophageal Diseases, Jiaotong University Expertise in General Thoracic Surgery: Full range of thoracic procedures. Exclusive experience in the following: 1. Minimally invasive (including Robotic) thoracic surgery. 2. Pulmonary resection for benign and malignant diseases. 3. Systemic lymph node dissection for esophageal cancer. 4. Anti-reflux procedures for GERD. 5. Thymectomy for thymoma and myasthenia gravis. Educational involvement Postgraduate program at the Shanghai Jiaotong University Medical School CME program in general thoracic surgery, Shanghai Chest Hospital Faculty member, Asian Thoracoscopic Surgery Education Program (ATEP) Academic positions: Secretary, Steering Committee member, International Thymic Malignancy Interest Group (ITMIG) Member, International Association of Study for Lung Cancers (IASLC) Member, International Society for Diseases of the Esophagus (ISDE) Executive committee member, Esophageal Cancer Committee, Chinese Anticancer Association Program Committee member, European Society of Thoracic Surgeons (ESTS) Faculty member, Asian Thoracoscopic Surgery Club (ATSC) Editorial Board Membership: 《Journal of Thoracic Diseases》Associate Editor in Chief《Annals of Thoracic Surgery》《Gastrointestinal Research》《World Journal of Gastrointestinal Surgery》《Chinese Medical Journal》《Chinese Journal of Surgery》《Chinese Journal of Gastrointestinal Surgery》International Advisory Board Member for《Asian Cardiovascular and Thoracic Annals.
About Dr. Andrea Ferraris
Biography Coming Soon.
About Dr. Pier Luigi Filosso
Pier Luigi Filosso, M.D. is Associate Professor of Thoracic Surgery at the Medical Faculty of the University of Torino (Italy). He is also the Chair of the European Society of Thoracic Surgeons (ESTS) Lung Neuroendocrine Tumors Working Group; he was the Secretary of the International Thymic Malignancy InterestGroup (ITMIG). He is an active Member of the most important International Thoracic Scientific Societies: the Italian Society of Thoracic Surgery (SICT), the European Society of Thoracic Surgeaons (ESTS); the International Association for the Study of Lung Cancer (IASLC); the Society of Thoracic Surgeons (STS);the International Thymic Malignancy Interest Group (ITMIG). His fields of interests are: Thoracic Oncology, Lung and Thymic NETs, Surgical Treatment of Lung, Mediastinal and Pleural Neoplasms, Emphysema and Management of Thoracic Trauma. He publised 165 papers in International peer reviewed journals on Thoracic Oncology issues.
About Dr. Giuseppe Giaccone
Biography Coming Soon.
About Dr. Nicolas Girard
Nicolas Girard is Professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and Senior Attending Physician in the Thoracic Oncology Service of the Hospices Civils de Lyon. He serves as the Head of Research of the Institute of Oncology at the Hospices Civils de Lyon. Nicolas Girard received his MD degree from the University of Lyon in 2005. He then performed fellowships in Respiratory Medicine and Medical Oncology. From 2007 to 2009, he joined the laboratory of Dr. William Pao at Memorial-Sloan Kettering Cancer Center, in New York, where he specialized in the field of Molecular Biology and Personalized Medicine. Among multiple projects, he performed a comprehensive genomic analysis of thymic malignancies. Nicolas Girard, as Vice-President of ITMIG from 2010 to 2014, has served in several committees, including the prospective database, the virtual tumor bank, and the research committees; more recently he has been involved in the development of the biology/basic science group. Nicolas Girard is coordinator of RYTHMIC, a French nationwide network for the management of these tumors. Nicolas Girard has published more than 100 articles and 15 book chapters in the field of thoracic oncology, and is a member of the editorial board of the Journal of Thoracic Oncology and Lung Cancer.
About Dr. Michael Lanuti
Dr. Lanuti is the Director of Thoracic Oncology in the Division of Thoracic Surgery at the Massachusetts General Hospital. He holds a parallel appointment as Associate Professor of Surgery at the Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004. He directs a translational Thoracic Oncology Research Laboratory that focuses on defining molecular risk of recurrence in early stage NSCLC, esophageal cancer, thymoma and solitary fibrous tumors of the pleura.
About Dr. Patrick Loehrer
Biography Coming Soon.
About Dr. Giuliano Maggi
Biography Coming Soon.
About Dr. Mirella Marino
Mirella Marino, MD, is Senior Staff Pathologist at the Regina Elena National Cancer Institute (IRE-NCI), Rome, Italy. After receiving her medical degree in Rome, University “La Sapienza”, she completed the residency in Pathology and later in Haematology at the Catholic University of Rome. She served first as Pathology Assistant at the S. Giacomo Hospital in Rome, then at the IRE-NCI, Rome, Italy. M. Marino was trained in Haematopathology/Thymic Pathology during several short stages at the Kiel Christian-Albrechts-Universität, Pathology Institute, leaded by Prof Dr K Lennert, and at the Julius-Maximilians-Universität, Würzburg, Germany, at the Pathology Institute leaded by Prof. Dr HK Müller Hermelink. In 1983 she was fellow of the Deutsches Akademisches Austauschdienst (DAAD) in Kiel for a research project on Thymic Epithelial Tumors (TET). In 1990-1993 she was Professor by contract of Histology and Embriology at “La Sapienza“ Medical School, University of Rome. M. Marino is involved in diagnostic surgical pathology of every organ/system. Moreover, she is the referral Pathologist for Haematopathology and for Thymic Epithelial Tumors (TET). She contributed to the 2015 WHO TET classification. M. Marino holds the membership and Committees contribution in International Thymic Malignancy Interest Group (ITMIG), in International Association of Study for Lung Cancer (IASLC), in European Society of Pathology (ESP);in Italian Society of Pathological Anatomy (SIAPEC); she is Member of the IASLC Staging and Prognostic Factors Committee, Thymic Domain (SPFC-TD).M. Marino also serves on the editorial board of “Mediastinum”(AME).
About Dr. Alex Marx
CV of Alexander Marx, MD University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany A. Current title and address Professor of Pathology, Chairman Institute of Pathology, University Medical Centre Mannheim University of Heidelberg D-68167 Mannheim, Germany B. Academic degree 1982, Medical Doctor (MD), University of Bonn, Bonn, Germany C. Studies and Positions 1975-1981 Medical School, University of Bonn, Bonn, Germany 1979-1982 MD Thesis, Institute of Physiological Chemistry, University of Bonn, Bonn Germany 1982-1983 Internship, Pediatrics, Children’s Hospital, St. Augustin, Germany 1984-1986 Assistant in Pathology and Physiology, University of Ulm, Ulm Germany 1987-1995 Assistant, 1995-1999 Assistant Professor,1998-2006 Vice-chairman (to Prof. Müller-Hermelink), 1999-2006 Associate Professor, Institute of Pathology, University of Würzburg, Germany 2006-present Director, Institute of Pathology, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany Main Research Interests: – Pathology, immunology and molecular biology of thymic tumors and of sarcomas – Cellular and molecular pathogenesis of the autoimmune disease, Myasthenia Gravis D. Honors 08-2001 Visiting Professorship, New York University, New York City, NY, USA 2015 Co-Editor, WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, IARC Press, Lyon, France 2008-2016 Reference pathologist, MGTX trial (Thymectomy in non-thymomatous Myasthenia gravis) 2013-2016 Co-chair, pathology group, TCGA project (thymoma, thymic carcinoma).
About Dr. Meinoshin Okumura
Born in 1958 in Osaka, Japan.
Graduated from Osaka University School of Medicine in 1984, and received training of general surgery, thoracic surgery, and cardiac surgery for 6 years from 1984 to 1990 at Osaka University Hospital and the affiliated hospitals.
Started to work as a research fellow in Osaka University School of Medicine in 1992, and received PhD degree in 1993. Major subjects were T cell development in the thymus and thymoma, the biological function of the thymus and thymoma in pathogenesis of myasthenia gravis, and pathology of thymic epithelial tumors.
Worked as a post-doctoral research fellow in Howard Hughes Medical Institute and Department of Pathology at Washington University in St. Louis, USA, from 1993 to 1996, and engaged in molecular biological research of immunology focusing on signal transduction.
Worked as an assistant professor of general thoracic surgery in Department of Surgery at Osaka University Hospital from 1996 to 2002, and in Center for Chest Diseases in Osaka as a chief surgeon from 2002 to 2004. Returned to Osaka University Hospital as associate professor of Department of Surgery in 2004. Promoted to Professor of Department of General Thoracic Surgery in 2007.
Currently, engaged in clinical practice of general thoracic surgery and lung transplantation and also in research of oncology, immunology and regenerative medicine.
In the academic society, serving for Japanese Association for Chest Surgery (JACS) as Secretary General, and also for Japanese Association for Study of the Thymus (JART) as Secretary General, and working as a manager of Administrating Office of Japanese National Registry of Lung Cancer. Had served for International Thymic Malignancy Interest Group (ITMIG) as a steering committee member, and managed an annual conference in Fukuoka in 2012. Currently, serving for European Society of Thoracic Surgeons (ESTS) as a regent from Japan.
About Dr. Sukhmani Padda
Sukhmani (Suki) Padda MD is an Assistant Professor of Medicine in the Department of Medicine, Division of Oncology at Stanford University. She graduated from a 6-year medical program, Northeastern Ohio Medical University in 2007. She completed internal medicine residency and hematology/oncology fellowship at Stanford University in 2014. She leads clinical trials in thoracic oncology and also has a significant interest in rare thoracic tumors, including neuroendocrine tumors of the lung and thymic malignancies. She has been an active member of the International Thymic Malignancy Interest Group (ITMIG) and is currently serving the role as ITMIG Councilor.
About Dr. Giovannella Palmieiri
Prof. Giovannella Palmieri has carried out many researches about non – Hodgkin lymphoma, sarcoma, epithelial tumors and biological therapy for cancer. She takes part in different research projects in the field of rare tumors, dealing with particularly epithelial thymic tumors and associated syndromes, sarcomas, neuroendocrine tumors and germ cell tumors. Due to high expertise in rare tumors, she founded in accordance with Campania Regional Law, the CRTR (Rare Tumors Reference Center); in 2016, she received the endorsement of the Ministry of Health to the application of the reference center to Europe (ERN- European Reference Network). She is the pioneer in management of rare tumors. She has organized monothematic conferences of rare tumors (neuroendocrine and germinal tumors), and organized the I and II Mediterranean Conference on Rare Tumors (Naples, 2011 and 2013). She encouraged the establishment of rare tumor patients associations, due to their role in governance of rare tumors, according to ECPC (European Cancer Patient Coalition), such as the newborn AITT (Italian Testicular Tumor Association). Moreover, she is patient coordinator in the oncological unit of AOU Federico II as concerns the excellence center of ENETS (European Neuroendocrine Tumor Society). She’s author of different scientific articles and active member of ITMIG (International thymic malignancies interest group) and IART (Italian association rare tumours).
About Dr. Mauro Papotti
Born Torino, July 5, 1955, married, three children. Present position: Full Professor of Pathology, University of Turin & Head, Division of Pathology, Città della Salute Hospital, Turin, Italy.
Vice-Chair, Medical School, University of Turin
Specializations: Oncology (1983) and Pathology (1991).
Diagnostic activity – Exfoliative and FNA diagnostic cytology; thoracic and endocrine surgical pathology. Application of immunohistochemistry and molecular techniques to histological and cytological specimens for diagnostic, prognostic and predictive purposes.
Teaching activity – Pathology courses at the University of Turin First Medical School in Turin (years 1992-2003 and from 2015-date) and Second Medical School in Orbassano (from 1997-date). Pathology course at the Laboratory Technician School, University of Turin (1994-date). Cytopathology and surgical pathology courses at the Post-graduate Schools in Pathology, Oncology, Respiratory Medicine, Thoracic Surgery and Endocrinology (years 1987-date).
Scientific activity – Thoracic pathology (lung and mesothelium), Endocrine pathology (parathyroid, thyroid and adrenal glands as well as neuroendocrine tumors) and immunohistochemical and molecular biology techniques applied to diagnostic pathology and aspiration biopsy cytology. Receptor analysis in endocrine tumors.
Over 400 papers in peer review journals e 420 abstracts.
Member of the International Academy of Pathology (IAP), European Society of Pathology (ESP), Società Italiana di Anatomia Patologica (SIAPEC), Endocrine Pathology Society, International Association for the Study of Lung Cancer (IASLC), European Neuroendocrine Tumor Society (ENETS).
Since 1982 obtained grants for research projects funded by the National Research Council (Rome), the Italian Ministry of University and Education, the Regione Piemonte (Turin), Fondazione Berlucchi and the Associazione italiana per la ricerca sul cancro (AIRC, Milan).
Member of the Editorial Board of Pathologica, Virchows Archives, Archives of Pathology, J Endocrinological Investigations, American Journal of Clinical Pathology, Journal of Pathology, J Clinical Pathology.
1990-1999 Secretary and 2000-2003 President of the “European School of Pathology (EScoP)”, founded in Torino by the European Society of Pathology (ESP).
About Dr. Giulia Pasello
Specialized in Medical Oncology in 2010 and currently Assistant Medical Director at Istituto Oncologico Veneto in Padova (Italy) since 2007, involved in clinical management and research of thoracic cancer patients.
Principal Investigator of several clinical trials on lung cancer, thymic malignancies and malignant pleural mesothelioma, and involved in translational studies aiming at the identification of molecular targets and innovative drugs of malignant mesothelioma.
Recipient of European and national awards for research projects on rare thoracic tumors.
About Dr. Ugo Pastorino
Ugo Pastorino graduated in Medicine in 1979 at the University of Milan and specialised in Emergency Surgery, Oncology and Thoracic Surgery. In 1991 launched the International Registry of Lung Metastases. Appointed as consultant thoracic surgeon at the Royal Brompton Hospital of London in 1994, is Director of Thoracic Surgery at the Istituto Nazionale Tumori of Milan from 2003, and Scientific Director in 2014/2015. From 2001 to 2014 was Associate Editor of the Journal of the National Cancer Institute, and from 2014 is Editor in Chief of Tumori Journal. Author of 332 papers with Impact Factor (H-index: 48), has been principal investigator of a number of randomised trials on chemoprevention and adjuvant chemotherapy, and is presently responsible of three prospective trials on lung cancer screening with LDCT and circulating biomarkers.
About Dr. Umberto Ricardi
Dr. Ricardi is currently Full Professor and Chairman of Radiation Oncology at University of Turin, Italy.
He is also serving as Director of the Department of Oncology at Health and Science Academic Hospital in Turin.
Dr. Ricardi’s main areas of clinical and scientific interest include lymphoma, lung cancer, CNS tumors. He is also an expert in the development of cutting edge technologies in Radiation Oncology.
Dr. Ricardi has authored more than 220 full research papers, and participated as invited speaker in a number of national and international conferences. He is active in many educational activities, both at national and international level.
Dr. Ricardi is member of numerous national and international scientific societies.
Dr. Ricardi is member of the Steering Committee of ILROG (International Lymphoma Radiation Oncology Group).
Dr. Ricardi is member of ART (Advanced RadioTherapy) Committee of IASLC.
Dr. Ricardi is President elect of ESTRO (European SocieTy for Radiotherapy and Oncology)
About Dr. Andreas Rimner
Andreas Rimner, M.D., is an Assistant Attending in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC). A native of Germany, he earned his medical degree at the Eberhard Karls University of Tuebingen. In 2003, he joined the laboratory of Dr. Zvi Fuks for a postdoctoral fellowship in radiation biology, after which he went on to complete his residency in radiation oncology at MSKCC. In 2010, Dr. Rimner joined the faculty as the primary thoracic radiation oncologist in the Department of Radiation Oncology at MSKCC. He is an expert on radiation therapy for rare thoracic malignancies, including thymic malignancies and malignant pleural mesothelioma. He joined ITMIG in 2010 and has led the ITMIG Thymic Carcinoma Working Group since 2013. He is the recipient of the 2014 ITMIG Barbara Neibauer Award for the Best Paper on Thymic Carcinomas.
About Dr. Enrico Ruffini
Biography Coming Soon.
About Dr. Giorgio Scagliotti
Prof Giorgio Scagliotti is Professor of Medical Oncology at the University of Torino in Italy and is also a member of the Academy of Medicine at the same University. He is currently the Chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino) and Head of the Department of Oncology at the University of Torino. Prof. Scagliotti earned his medical degree and completed his postgraduate training in respiratory medicine, internal medicine and medical oncology at the University of Torino.
Over the last 25 years, his research interests have included experimental studies on basic and clinical applied research on lung cancer, including translational research. He has been or is currently the study coordinator of several European and international clinical trials on lung cancer chemotherapy; he has also served as a key investigator in several Italian studies examining the role of chemotherapy in early stage non-small cell lung cancer.
Prof. Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, European Respiratory Society (ERS), American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC). From 2002 to 2005, he was a member of the International Affair Committee of ASCO and, from 2003 to 2007, an Executive Board member of IASLC. He also served on the Publication Committee (2005–2008) and on the Program Committee of ASCO (2005–2007). He is currently the President-Elect of IASLC (2015-2017)
About Dr. Charles Simone II
Dr. Charles B. Simone, II is the Medical Director of the Maryland Proton Treatment Center, an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine. He is also the Fellowship Director and the Director of the Stereotactic Radiation Therapy Program for the Department of Radiation Oncology. He completed his undergraduate and medical school training at the University of Pennsylvania. He completed an internship in internal medicine and then residency training in radiation oncology at the National Cancer Institute, National Institutes of Health, where he served as chief resident. Prior to his appointment at University of Maryland, Dr. Simone was an Associate Professor of Radiation Oncology, Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Co-Director of the Penn Mesothelioma and Pleural Program for the University of Pennsylvania Health System, and Director of Clinical Research and Operations for the Department of Radiation Oncology at Penn.
Dr. Simone is an National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for thoracic malignancies. He is the Chair of the Proton Collaborative Group (PCG) Executive Committee, Chair of the PCG Lung Committee, and Chair of the American Society for Photobiology (ASP) Education Committee. He is appointed to the NRG Oncology (formerly Radiation Therapy Oncology Group [RTOG]) Lung Cancer Core Committee; NRG Radiation Oncology Committee; NCI Thoracic Malignancies Steering Committee Mesothelioma Working Group; International Thymic Malignancy Interest Group (ITMIG) Research and Infrastructure Committee; ITMIG Thymic Carcinoma Workgroup; American Society for Radiation Oncology (ASTRO) Lung Cancer “Blue Ribbon” Panel; ASP Executive Council; PCG Reirradiation Committee; Particle Therapy Co-Operative Group (PTCOG) Scientific Committee; and multiple PTCOG Clinical Subcommittees. He is the Editor-in-Chief of Annals of Palliative Medicine.
About Dr. Joshua Sonett
Dr. Sonett is Professor and Chief of thoracic surgery at Columbia University and, and is Director to the Price Family Center for Comprehensive Chest Disease. The center is dedicated to the multi-disciplinary care of patients with lung, diaphragm, esophageal, and thymic diseases. Columbia has long been an epicenter for the study of thymic diseases, and this contines as the lead surgical center for the international myathenias gravis trial.
About Dr. Heather Wakelee
Dr. Heather Wakelee is an Associate Professor of Medicine at Stanford University in the Division of Oncology where she leads the thoracic medical oncology research program and has authored or co-authored over 150 medical articles on thoracic malignancies. She attended Princeton University and then went to medical school at Johns Hopkins University. She returned to her native California for internal medicine residency and fellowship training in medical oncology at Stanford University. Dr. Wakelee’s focus is in clinical research in thoracic malignancies including lung cancer and thymic malignancies. Dr. Wakelee has led multiple investigator-initiated protocols looking at bevacizumab and other anti-angiogenic agents. Additional areas of interest include drugs and drug combinations focused on overcoming EGFR and ALK inhibitor resistance, Met inhibitors and novel immune modulatory agents. She serves on the steering committee and is the chair of the Research Working Group of the International Thymic Malignancies Interest Group (ITMIG) and has written and conducted multiple phase II trials of novel agents in this rare disease entity. She is very active in the American Society of Clinical Oncology (ASCO) and also serves on the Board of Directors of the International Association for the Study of Lung Cancer (IASLC).